Pacific Edge Reports Sequential Growth in Test Volumes for March Quarter

MT Newswires Live

04/10

Pacific Edge (ASX:PEB, NZE:PEB) said its total laboratory throughput, or volume of tests performed, increased 2.7% in the March quarter from the linked period to 5,582 tests, according to a Friday filing with the Australian bourse.

Volumes in the US gained 1%, mainly reflecting growth through the Kaiser Permanente Southern California

system, while Asia-Pacific volumes rose 7.7%, per the filing.

The improvement in test volumes came despite disruption caused by transitioning certain US customers and fewer operating days in the US, where a series of winter storms impacted operations, the company said.

Pacific Edge also said it saw "significant" commercial success in the US and Asia Pacific during the March quarter, including coverage of its Cxbladder Triage test by Blue Cross Blue Shield North Carolina and the incorporation of its Triage, Triage Plus, and Monitor offerings by Singapore General Hospital.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2626156744"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2626156744\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2626156744?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 07:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626156744","market":"sg","top_or_hot":-1,"title":"Pacific Edge Reports Sequential Growth in Test Volumes for March Quarter","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PFGTF\">Pacific Edge</a> (ASX:PEB, NZE:PEB) said its total laboratory throughput, or volume of tests performed, increased 2.7% in the March quarter from the linked period to 5,582 tests, according to a Friday filing with the Australian bourse.</p><p>Volumes in the US gained 1%, mainly reflecting growth through the Kaiser Permanente Southern California</p><p>system, while Asia-Pacific volumes rose 7.7%, per the filing.</p><p>The improvement in test volumes came despite disruption caused by transitioning certain US customers and fewer operating days in the US, where a series of winter storms impacted operations, the company said.</p><p><a href=\"https://laohu8.com/S/PEB.AU\">Pacific Edge</a> also said it saw \"significant\" commercial success in the US and Asia Pacific during the March quarter, including coverage of its Cxbladder Triage test by Blue Cross Blue Shield North Carolina and the incorporation of its Triage, Triage Plus, and Monitor offerings by Singapore General Hospital.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacific Edge Reports Sequential Growth in Test Volumes for March Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacific Edge Reports Sequential Growth in Test Volumes for March Quarter\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-10 07:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PFGTF\">Pacific Edge</a> (ASX:PEB, NZE:PEB) said its total laboratory throughput, or volume of tests performed, increased 2.7% in the March quarter from the linked period to 5,582 tests, according to a Friday filing with the Australian bourse.</p><p>Volumes in the US gained 1%, mainly reflecting growth through the Kaiser Permanente Southern California</p><p>system, while Asia-Pacific volumes rose 7.7%, per the filing.</p><p>The improvement in test volumes came despite disruption caused by transitioning certain US customers and fewer operating days in the US, where a series of winter storms impacted operations, the company said.</p><p><a href=\"https://laohu8.com/S/PEB.AU\">Pacific Edge</a> also said it saw \"significant\" commercial success in the US and Asia Pacific during the March quarter, including coverage of its Cxbladder Triage test by Blue Cross Blue Shield North Carolina and the incorporation of its Triage, Triage Plus, and Monitor offerings by Singapore General Hospital.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEB.AU","symbol_name":"PACIFIC EDGE LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2626156744","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626156744","pubTimestamp":1775778154,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pacific Edge  said its total laboratory throughput, or volume of tests performed, increased 2.7% in the March quarter from the linked period to 5,582 tests, according to a Friday filing with the Australian bourse.Volumes in the US gained 1%, mainly reflecting growth through the Kaiser Permanente Southern Californiasystem, while Asia-Pacific volumes rose 7.7%, per the filing.The improvement in test volumes came despite disruption caused by transitioning certain US customers and fewer operating days in the US, where a series of winter storms impacted operations, the company said.Pacific Edge also said it saw \"significant\" commercial success in the US and Asia Pacific during the March quarter, including coverage of its Cxbladder Triage test by Blue Cross Blue Shield North Carolina and the incorporation of its Triage, Triage Plus, and Monitor offerings by Singapore General Hospital.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEB.AU":"PACIFIC EDGE LTD","BK7067":"生物科技","BK8033":"生物科技","PEB.NZ":"Pacific Edge Limited Ordinary Shares"},"translate_title":"Pacific Edge报告三月份季度测试量环比增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEB.AU":1,"PEB.NZ":1.5},"content_text":"Pacific Edge (ASX:PEB, NZE:PEB) said its total laboratory throughput, or volume of tests performed, increased 2.7% in the March quarter from the linked period to 5,582 tests, according to a Friday filing with the Australian bourse.Volumes in the US gained 1%, mainly reflecting growth through the Kaiser Permanente Southern Californiasystem, while Asia-Pacific volumes rose 7.7%, per the filing.The improvement in test volumes came despite disruption caused by transitioning certain US customers and fewer operating days in the US, where a series of winter storms impacted operations, the company said.Pacific Edge also said it saw \"significant\" commercial success in the US and Asia Pacific during the March quarter, including coverage of its Cxbladder Triage test by Blue Cross Blue Shield North Carolina and the incorporation of its Triage, Triage Plus, and Monitor offerings by Singapore General Hospital.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}